Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Business Wire•06/10/2026•08:30 ET
0
Key Highlights
- ➤ZUNVEYL data to be presented at ASCP Annual Meeting and NEI Fall Congress
- ➤Presentations cover cognition, function, symptoms, sleep, tolerability, and medication utilization
- ➤ASCP program includes nine posters on benzgalantamine and Alzheimer’s treatment patterns
- ➤NEI program includes two BEACON Study posters on cognitive and functional outcomes
Expert Statements
Denis Kay, Chief Scientific Officer of Alpha Cognition
“The breadth of data being presented at ASCP and NEI Fall Congress reflects our continued commitment to building the scientific evidence around ZUNVEYL”
Denis Kay, Chief Scientific Officer of Alpha Cognition
“These analyses examine multiple aspects of treatment in Alzheimer’s disease, including cognition, function, neuropsychiatric symptoms, sleep, tolerability and medication utilization, and provide additional real-world insights that can help inform our understanding of ZUNVEYL use in clinical practice.”
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Presentations will highlight data on cognition, function, neuropsychiatric symptoms, sleep, gastrointestinal tolerability, treatment patterns and psychotropic medication utilization in Alzheimer’s disease
Get started
Create a free account to read the full story.